{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:29:04Z","timestamp":1790094544858,"version":"4.0.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Clobazam is a benzodiazepine derivative used as an antiepileptic agent for the treatment of focal and generalized seizures and drug-resistant epilepsy associated with Lennox-Gastaut Syndrome. While somnolence and mood-related side effects are commonly observed, acute macroglossia following initiation of Clobazam therapy has not been previously reported in the medical literature. In this case report, we present a female pediatric patient who developed significant tongue swelling with protrusion beyond the oral cavity after initiation of Clobazam for treatment-resistant epilepsy. Symptoms were unresponsive to antihistamines and steroids but resolved gradually in the days following discontinuation of Clobazam with no lingering sequelae.<\/jats:p>","DOI":"10.3389\/fneur.2022.900763","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T07:03:23Z","timestamp":1652079803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Macroglossia Associated With Clobazam Administration: A Case Report and Literature Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jeff F.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Nickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Piryani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Swayampakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1875-595X.2011.00015.x","article-title":"Macroglossia","volume":"61","author":"Topouzelis","year":"2011","journal-title":"Int Dent J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6040354","DOI":"10.1155\/2019\/6040354","article-title":"Self-induced traumatic macroglossia: case report and literature review","volume":"2019","author":"Alarfaj","year":"2019","journal-title":"Case Rep Otolaryngol."},{"key":"B3","volume-title":"Clobazam","author":"Humayun","year":"2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e88456","DOI":"10.1371\/journal.pone.0088456","article-title":"Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for alpha- versus alpha-GABA(A)-receptor complexes","volume":"9","author":"Jensen","year":"2014","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5863\/1551-6776-25.6.485","article-title":"Emerging use of epidiolex (cannabidiol) in epilepsy","volume":"25","author":"Abu-Sawwa","year":"2020","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"B8","article-title":"Clobazam therapy and CYP2C19 Genotype","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"key":"B9","year":"2012"},{"key":"B10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/epi.13316","article-title":"Clobazam-induced pedal edema: \u201cAn unrecognized side effect of a common antiepileptic drug\u201d","volume":"57","author":"Mathew","year":"2016","journal-title":"Epilepsia. Mar."},{"key":"B11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s13760-018-0901-4","article-title":"Unusual side effects due to clobazam: a case report with edema of the extremities","volume":"118","author":"Incecik","year":"2018","journal-title":"Acta Neurol Belg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/00003246-200205000-00008","article-title":"Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam","volume":"30","author":"Agelink","year":"2002","journal-title":"Crit Care Med. May."},{"key":"B13","doi-asserted-by":"publisher","first-page":"909A","DOI":"10.1378\/chest.1698580","article-title":"A case of acute tongue enlargement","volume":"144","author":"Darshan","year":"2013","journal-title":"Chest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/MJT.0000000000001094","article-title":"Phenobarbital-associated macroglossia","volume":"28","author":"Parthvi","year":"2021","journal-title":"Am J Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2710.2006.00712.x","article-title":"Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach","volume":"31","author":"Yukawa","year":"2006","journal-title":"J Clin Pharm Ther"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.900763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T07:03:25Z","timestamp":1652079805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.900763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":16,"alternative-id":["10.3389\/fneur.2022.900763"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.900763","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"900763"}}